Table 2.
The prevalence of patients using medication targeting obstructive lung disease
| Women | Men | Total | ||
|---|---|---|---|---|
| (95% CI) (n/N) | (95% CI) (n/N) | P | (95% CI) (n/N) | |
| Total prevalence (%), 20–79 years | 10.4 (9.9–10.8) (1,845/17,757) |
4.9 (4.7–5.2) (1,010/20,407) |
<0.001 | 7.5 (7.2–7.7) (2,855/38,164) |
| Prevalence (%) in age groups | ||||
| 20–29 years | 4.9 (4.2–5.5) (198/4,080) |
2.1 (1.7–2.5) (91/4,341) |
<0.001 | 3.4 (3.0–3.8) (289/8,421) |
| 30–39 years | 7.9 (7.0–8.8) (292/3,700) |
3.2 (2.7–3.8) (126/3,936) |
<0.001 | 5.5 (5.0–6.0) (418/7,636) |
| 40–49 years | 9.5 (8.4–10.7) (257/2,692) |
4.1 (3.4–4.8) (133/3,230) |
<0.001 | 6.6 (6.0–7.2) (390/5,922) |
| 50–59 years | 12.8 (11.8–13.8) (532/4,157) |
5.1 (4.4–5.7) (249/4,920) |
<0.001 | 8.6 (8.0–9.2) (781/9,077) |
| 60–69 years | 16.98 (15.41–18.55) (371/2,185) |
9.9 (8.8–11.0) (278/2,819) |
<0.001 | 13.0 (12-0-13.9) (649/5,004) |
| 70–79 years | 20.7 (18.1–23.3) (195/943) |
11.5 (9.6–13.3) (133/1,161) |
<0.001 | 15.6 (14.0–17.1) (328/2,104) |
| 80+ years | 16.6 (12.4–20.7) (51/308) |
18.9 (13.7–24.1) (41/217) |
0.488 | 17.5 (14.3–20.) (92/525) |
| Young (%), 20–39 years | 6.30 (5.8–6.8) (490/7780) |
2.6 (2.3–3.0) (217/8,277) |
<0.001 | 4.4 (4.1–4.7) (707/16,057) |
| Seniors (%), 40–79 years | 13.6 (12.9–14.3) (1,355/9,977) |
6.5 (6.1–7.0) (793/12,130) |
<0.001 | 9.7 (9.3–10.1) (2,148/22,107) |
95% CI = 95% confidence intervals, n/N = number of patients/population, P = p-values.